Trials / Recruiting
RecruitingNCT06874231
Brain Connectivity Marker for Alzheimer's Disease
Clinical Application of a Brain Connectivity Marker for Early Detection of Alzheimer's Disease
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- Karolinska Institutet · Academic / Other
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).
Detailed description
To achieve this aim, the investigators will perform six different studies that have been designed to achieve the following specific objectives: 1.1. Identify changes of brain connectivity in individuals who show abnormal AD amyloid biomarkers in the cerebrospinal fluid and blood. 1.2. To assess the correlation between brain connectivity changes and biomarkers of synaptic dysfunction and inflammation as well as alterations of electrical brain signals. 1.3. Establish whether alterations of brain connectivity could be improved after patients start treatment with cholinesterase inhibitors. 1.4. Assess differences in brain connectivity between patients receiving treatment with statins and those not taking this medication. 1.5. Determine whether brain connectivity changes can predict longitudinal cognitive decline and conversion to AD dementia. 1.6. Assess whether different microorganisms can grow more rapidly in the cerebrospinal fluid from AD patients compared to controls and whether their levels are associated with brain connectivity. 1.7. Evaluate the relationship between brain connectivity and the integrity of the locus coeruleus, which is the earliest site of AD pathology
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Neuroimaging | The investigators will collect imaging sequence, cognitive test scores, clinical data and biofluid samples |
Timeline
- Start date
- 2023-04-01
- Primary completion
- 2027-07-31
- Completion
- 2027-07-31
- First posted
- 2025-03-13
- Last updated
- 2025-03-17
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT06874231. Inclusion in this directory is not an endorsement.